Spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications.


Our Pipeline and Products

Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are three products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology. Learn more »

Spectrum has three drugs in advanced development:

Poziotinib for a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer. Learn more »
ROLONTIS® (eflapegrastim)
ROLONTIS® (eflapegrastim), being developed for chemotherapy-induced neutropenia in patients with breast cancer. Learn more »
Apaziquone for Intravesical Instillation, being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Learn more »

Expanding Patient Options

Our passion to deliver additional options for patients suffering from cancer is behind every action we take. We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrum philosophy.

The Spectrum Philosophy